Investors share how health startups at an early stage use AI

In a recent webinar organized by Medcity News and sponsored by the commercial bank provider * Mercury, the venture capital shared their prospects on trends in the health, medtech and biopharma technology sector that have aroused their interest and funding. They also offered advice to startups looking for alternative funding sources beyond government grants.

Artificial intelligence and the impact of automation on long tasks, in particular to identify the objectives of the development of drugs, were another important part of the discussion.

Gurdane Bhutani is a managing director of MBX Capital, a venture capital fund at an early stage focused exclusively on health care and biotechnology companies which pursue the deep causes of the reasons why people fall sick. Bhutani noted that the company is investing in three verticals: engines upstream of the results of human health; Health technology companies that use AI to increase the quality of care; And research tools in biotechnology, diagnosis and therapy. Bhutani’s formation focused on epidemiology and toxicology.

Morgan Cheatham is a partner and head of health care and life sciences with Breyer Capital, a venture capital company founded by Jim Breyer, one of the first Facebook investors. It focuses on investment in startups at the start of the stage at the intersection of health care, life sciences and technology. Two of its main principles of investment organization are the medicine of AI and precision. Cheatham is also formed as a doctor in genetics.

Ben Kromnick has built megadata and automatic learning platforms with Fortune health and insurance companies 100 before becoming founder, investor and operator of several clinical research and DSE research companies. He worked with some of the largest sets of clinical data, health systems and pharmaceutical companies. Using this experience, he built health and life science affairs at Mercury.

In the webinar, the panelists highlighted the investment and collaboration strategies of their companies’ health startups. Although AI is a dominant theme of the discussion, the panelists have focused on the direct impact of its applications specialized in the field and their impact on the evaluations of actions and business development strategies.

“If you are a company that focuses on the autoimmune space and develop a modular agent, you must worry about immunogenicity as a key risk for your program,” noted Cheatham. “Instead of focusing on AI as a large platform entity in several areas of indication, this company can rather develop highly specialized models which specifically target the reduction of immunogenicity for their program, because this is where they can increase the probability of success.”

Cheatham has also stressed the importance of in vivo validation data which animate a large part of the external commercial development efforts that its companies are launching in biopharmacy companies. This In Vivo data is piloting the next financing steps for startups.

Some of the other points for discussion of the webinar included:

• Grant financing secrets
• Capital assessment
• Similar starting tips for effective growth
• Use of AI to reduce the risk
• The role of families

To access a web-registration, fill out the form below.

*Mercury is a financial technology company, not a bank. Banking services are provided via Choice Financial Group, Column Na, and Evolve Bank & Trust, FDIC members.

Photo: Alan Thornton, Getty Images